May 2, 2024Cancer Research

Abstract PO1-29-01: Single agent and combinatorial efficacy with imipridone ONC206 via inhibition of mitochondrial function in preclinical models of chemorefractory triple negative breast cancer

View Full Paper

Ask AI

Bookmark

Mitochondrial fusion and oxidative phosphorylation decrease following ONC206 exposure, which restores chemosensitivity in resistant triple negative breast cancer cells.
Tumor growth decreased across 3 patient derived xenograft models with 100 mg/kg ONC206, producing near-complete tumor regression alongside carboplatin in BCM-2665.
Highlights therapeutic potential for targeting clpp to overcome drug resistance, though efficacy is demonstrated in mouse models and warrants clinical validation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical evaluation shows tumor growth inhibition from ONC206 in triple-negative breast cancer xenografts, highlighting a mitochondrial strategy against chemoresistance.

Cite This Study

Baek et al. (2024) studied this question.

synapsesocial.com/papers/68e6be94b6db64358763e6aa https://doi.org/10.1158/1538-7445.sabcs23-po1-29-01

View Full Paper

Ask AI

Bookmark

Implication

Preclinical evaluation shows tumor growth inhibition from ONC206 in triple-negative breast cancer xenografts, highlighting a mitochondrial strategy against chemoresistance.

Abstract PO1-29-01: Single agent and combinatorial efficacy with imipridone ONC206 via inhibition of mitochondrial function in preclinical models of chemorefractory triple negative breast cancer

Key Points

Discussion

Implication

Cite This Study

Abstract PO1-29-01: Single agent and combinatorial efficacy with imipridone ONC206 via inhibition of mitochondrial function in preclinical models of chemorefractory triple negative breast cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider